Is Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now?
21 Stocks to Play a 'Magical Moment' in Healthcare -- Barrons.com
Weight loss candidate drug nimacimab safety approved. Skye (SKYE.US) stock price soared 11%.
Skye Bioscience's stock price soared 11%, benefiting from the safety differences between its weight loss candidate drug nimacimab and novo-nordisk a/s's monlunabant.
Sector Update: Health Care Stocks Retreat Late Afternoon
Morgan Stanley Starts Structure Therapeutics at Overweight
Skye Stock Rallies 22% Following Weight-loss Drug Update
Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $65
Cantor Fitzgerald analyst Prakhar Agrawal maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success
Structure Therapeutics Price Target Announced at $118.00/Share by Morgan Stanley
Cantor Fitzgerald Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Morgan Stanley Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $118
Morgan Stanley analyst Terence Flynn initiates coverage on $Structure Therapeutics(GPCR.US)$ with a buy rating, and sets the target price at $118.According to TipRanks data, the analyst has a
Morgan Stanley Initiates Structure Therapeutics at Overweight
Viking, Structure, Terns Benefitting From Disappointing Novo Nordisk Weight Loss Data
High-Flying Novo Nordisk Dips On Disappointing Data for Weight-Loss Pill -- WSJ
Press Release: Structure Therapeutics Strengthens Executive Team With Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer
Express News | Structure Therapeutics Strengthens Executive Team With Promotion of Blai Coll, M.d., Ph.d. to Chief Medical Officer and Appointment of Ashley Hall, J.d. as Chief Development Officer
Do Queasy Side Effects Mean the End of Weight-loss Drug Stock Hype?
16 New GLP-1 Weight-loss Drugs Could Be Launched by 2029: Report
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $86
JMP Securities analyst Jonathan Wolleben maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $86.According to TipRanks data, the analyst has a success
Buy Rating on Structure Therapeutics: Promising GSBR-1290 Clinical Developments and Competitive Market Positioning
Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79
Jefferies analyst Roger Song maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $79.According to TipRanks data, the analyst has a success rate of 32.4%